Apple’s blood oxygen monitoring returns to its latest Apple Watches

Apple has reintroduced a redesigned Blood Oxygen feature for select Apple Watch Series 8, Series 10, and Ultra models, enabling data measurement on the watch but processing and viewing on a paired iPhone. This strategic software adjustment, cleared by a recent U.S. Customs ruling, allows Apple to circumvent an ITC import ban stemming from an ongoing patent infringement dispute with medical device maker Masimo, effectively restoring a key health feature for new sales after its prior removal.

Analysis

Apple has engineered a strategic workaround to the International Trade Commission's (ITC) import ban on its watches, effectively reintroducing the blood oxygen monitoring feature for new models sold in the U.S. by offloading data processing and viewing to a paired iPhone. This software-based solution, which has received clearance from U.S. Customs, significantly mitigates the commercial risk posed by the ban, allowing Apple to resume sales of its latest Watch Series 8, 10, and Ultra models with a key health-monitoring capability intact. While the user experience is slightly altered, this move represents a critical tactical victory for Apple in its ongoing patent infringement dispute with Masimo Corporation. The development substantially weakens Masimo's leverage, which was predicated on the financial pressure of the import ban. The core legal conflict, however, remains unresolved, with Apple's appeal of the ITC ban and its countersuit against Masimo still pending, indicating that this workaround is a maneuver within a larger, protracted battle over intellectual property in the lucrative wearables and health-tech market.

Key Decisions for Investors

• For Apple (AAPL) investors, this development de-risks the stock by neutralizing the immediate sales threat from the ITC import ban, underscoring the company's ability to innovate around regulatory and legal obstacles.
• Investors in Masimo (MASI) should recognize that the company's primary leverage in its litigation against Apple has been significantly diminished, which could negatively impact its prospects for a favorable or timely settlement.
• Traders should continue to monitor the ongoing legal proceedings, including Apple's appeal of the ITC ban, as the final outcome will still carry significant financial implications for both companies concerning potential damages or future royalty payments.